MENU
XPH
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

XPH stock forecast, quote, news & analysis

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
XPH
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for XPH with price predictions
Oct 16, 2026

XPH in -3.03% downward trend, falling for three consecutive days on October 14, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where XPH declined for three days, in 232 of 277 cases, the price declined further within the following month. The odds of a continued downward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day moving average for XPH crossed bearishly below the 50-day moving average on September 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.

The Aroon Indicator for XPH entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where XPH's RSI Oscillator exited the oversold zone, 18 of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +2.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where XPH advanced for three days, in 278 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

XPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the State Street SPDR S&P Pharmaceuticals ETF (XPH) ETF is 62.51B. The market cap for tickers in the group ranges from 285.36M to 1.06T. LLY holds the highest valuation in this group at 1.06T. The lowest valued company is EYPT at 285.36M.

High and low price notable news

The average weekly price growth across all stocks in the State Street SPDR S&P Pharmaceuticals ETF (XPH) ETF was -4%. For the same ETF, the average monthly price growth was -7%, and the average quarterly price growth was 5%. LQDA experienced the highest price growth at 25%, while CTNM experienced the biggest fall at -47%.

Volume

The average weekly volume growth across all stocks in the State Street SPDR S&P Pharmaceuticals ETF (XPH) ETF was 24%. For the same stocks of the ETF, the average monthly volume growth was 17% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 56
Price Growth Rating: 51
SMR Rating: 71
Profit Risk Rating: 70
Seasonality Score: 18 (-100 ... +100)
XPH in -3.03% downward trend, falling for three consecutive days on October 14, 2026